All In Biotech

BLA 761070 · Astrazeneca Ab

Fasenra

Benralizumab · Injection · Interleukin-5 Receptor alpha-directed Cytolytic Antibody

NovelOrphan

Last checked: Nov 20, 2026Latest source record: May 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Nov 14, 2017

Approved uses

5

Original approval plus efficacy supplements

Registered trials

73

37 Phase 3, 11 recruiting

FAERS reports

20,994

13,564 serious, 2,114 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 13, 2026.

FASENRA is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for: • add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype. ( 1.1 ) • treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.2 ) • treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause. ( 1.3 ) Limitations of Use : Not for relief of acute bronchospasm or status asthmaticus. (1.1) 1.1 Asthma FASENRA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype. Limitations of Use: • FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus. 1.2 Eosinophilic Granulomatosis with Polyangiitis FASENRA is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1.3 Hypereosinophilic Syndrome FASENRA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause.

Mechanism: Benralizumab is a humanized afucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα) with a dissociation constant of 11 pM. The IL-5 receptor is expressed on the surface of eosinophils and basophils. In an in vitro setting, the absence of fucose in the Fc domain of benralizumab facilitates binding (45.5 nM) to FcɣRIII receptors on immune effector cells, such as natural killer (NK) cells, leading to apoptosis of eosinophils and basophils through antibody-dependent cell-mediated cytotoxicity (ADCC). Inflammation is an...

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • FASENRA · BENRALIZUMAB 30MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Benralizumab" as an intervention, any sponsor and status, largest first.

All 73 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • asthma3,144
  • dyspnoea2,109
  • death1,738
  • drug ineffective1,580
  • pneumonia1,218
  • cough1,111
  • product dose omission issue1,078
  • headache973
  • wheezing791
  • fatigue679
  • malaise638
  • inappropriate schedule of product administration619

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20122
20131
20144
20153
20161
20174
2018910
20191,649
20201,709
20212,104
20221,827
20232,296
20243,669
20253,546
20263,269

Recalls

1 FDA enforcement reports for this application.

  • Oct 8, 2025 · Class II · Ongoing

    Lack of Assurance of Sterility:

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fasenra (Benralizumab)

2024 spending

$75.9M

Beneficiaries

3,087

13,139 claims

Per beneficiary

$24,574

$5,748.17 per unit

View as table
YearSpending
2020$43,358,082
2021$54,241,546
2022$65,644,342
2023$69,166,950
2024$75,859,049

Part B: Fasenra* (Benralizumab*) · HCPCS J0517

2024 spending

$241M

Beneficiaries

9,899

50,136 claims

Per beneficiary

$24,374

2024 ASP limit $167.57 per unit

View as table
YearSpending
2020$180,879,417
2021$197,482,084
2022$216,900,354
2023$231,829,729
2024$241,276,554

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 158 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.